Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Improved hemostasis in hemophilia mice by means of an engineered factor Va mutant.

Journal of thrombosis and haemostasis : JTH - 1 Jan 2014

von Drygalski A, Cramer T J, Bhat V, Griffin J H, Gale A J, Mosnier L O

Abstract excerpt

BACKGROUND: Factor (F)VIIa-based bypassing not always provides sufficient hemostasis in hemophilia. OBJECTIVES: To investigate the potential of engineered activated factor V (FVa) variants as bypassing agents in hemophilia A. METHODS: Activity of FVa variants was studied in vitro using prothrombinase assays with purified components and in FV- and FVIII-deficient plasma using clotting and thrombin generation...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Blood Coagulation
Share to Hemophilia A
Share to Hemostasis

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Partial Thromboplastin Time

Share to Protein C

Share to Prothrombin Time

Share to Thrombin

Share to Thromboplastin

Source

Open in PubMed Open full text

Identifiers

PMID: 24818532
DOI: 10.1111/jth.12489
PMCID: PMC4161283

Genes

APC

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Improved hemostasis in hemophilia mice by means of an engineered factor Va mutant.PMID 24818532Read ↗

Safety, Stability and Pharmacokinetic Properties of (super)Factor Va, a Novel Engineered Coagulation Factor V for Treatment of Severe Bleeding.Semantic proximity Read ↗

Engineered factor IX variants bypass FVIII and correct hemophilia A phenotype in mice.Semantic proximity Read ↗

Catalytic domain modification and viral gene delivery of activated factor VII confers hemostasis at reduced expression levels and vector doses in vivo.Semantic proximity Read ↗

Disulfide bond-stabilized factor VIII has prolonged factor VIIIa activity and improved potency in whole blood clotting assays.Semantic proximity Read ↗

A Thrombin-Activatable Factor X Variant Corrects Hemostasis in a Mouse Model for Hemophilia A.Semantic proximity Read ↗

The heparin-binding exosite of factor IXa is a critical regulator of plasma thrombin generation and venous thrombosis.Semantic proximity Read ↗

The severe spontaneous bleeding phenotype in a novel hemophilia A rat model is rescued by platelet FVIII expression.Semantic proximity Read ↗

An activated factor VII variant with enhanced tissue factor-independent activity speeds wound healing in a mouse hemophilia B model.Semantic proximity Read ↗

AAV mediated genome engineering with a bypass coagulation factor alleviates the bleeding phenotype in a murine model of hemophilia B.Semantic proximity Read ↗

Coagulation factor VIII: biological basis of emerging hemophilia A therapiesSemantic proximity Read ↗

Intrinsic stability and functional properties of disulfide bond-stabilized coagulation factor VIIIa variants.Semantic proximity Read ↗

Interaction of P-selectin and PSGL-1 generates microparticles that correct hemostasis in a mouse model of hemophilia A.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.